TARS vs USB · rev $183.0M vs P/E 12, rev $28.66B
Tarsus Pharmaceuticals Inc (TARS) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
TARS currently screens at market cap $2.66B. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the TARS and USB stock pages for the full models.
Not investment advice.